Open with the portfolio judgment: Novo Nordisk's GLP-1 holdings function as a thicket, not a moat. A moat is one or a few broad claims that genuinely block a competitor from a whole approach. A thicket is many narrow claims that, individually, are easy to design around but, collectively, make designing around all of them expensive and slow. Reading Novo's grants — multiple "GLP-1 compositions and uses" patents (US11752198B2, US10888605B2), a "Pharmaceutical formulations" grant (US12527844B2), and a spray-drying process grant (US12138349B2) — the pattern is unmistakably the latter.
Why no moat at the concept level? Because GLP-1 receptor agonism as a therapeutic strategy is old and broadly practiced; no current grant could plausibly claim the concept itself. What is claimable, and what Novo has claimed, are specific peptides, specific stabilized formulations, and specific manufacturing processes. Each is defensible on its own narrow terms, but none reaches the whole field. Confusing the volume of these grants with a single dominant claim is the most common error in reading the estate.
Aggregate before judging strength — the analyst's discipline. One formulation patent is not a strategy; the cluster is. When you line up the composition claims, the injectable-preparation formulation claims (CPC A61K 9/0019), and the process claims (spray-drying, A61K 9/1688), you see a deliberately layered defensive structure: cover the molecule, cover the shippable formulation, cover the way it is made. That layering is what raises a challenger's cost, because clearing one layer leaves the others standing.
The thicket's weakness is its strength inverted. Narrow claims are easier to invalidate or design around individually, so a well-resourced challenger can pick them off — invalidate a formulation claim here, design around a process claim there. The estate slows competition; it does not guarantee a block. A genuine moat would survive the loss of any single claim; a thicket degrades as claims fall. That is the honest read of portfolio strength here.
Continuations and divisionals matter to the audit. A thicket stays effective only if it is actively maintained and extended — new filings replacing or reinforcing claims as older ones near expiry. The presence of recent grants (the 2026 "Pharmaceutical formulations" patent) alongside older ones suggests an estate being refreshed, which is what keeps a thicket from thinning out as its earliest layers lapse.
The strategist's verdict: call Novo's GLP-1 estate what it is — a maintained defensive thicket of narrow composition, formulation, and process claims. It is a real and costly barrier to a fast follow-on, but it is not a moat around GLP-1 agonism, and its strength is distributed across many claims that each fall or hold on their own merits. Volume is not strength; the layered, actively-refreshed structure is.